Expanded vaccination and treatment could help eliminate hepatitis B worldwide
Global hepatitis B epidemic treatable at cost of just $36 per patient per year
Experimental siRNA therapy lowers HBsAg levels in people with hepatitis B
Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus
Tenofovir continues to suppress hepatitis B virus for eight years
Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients
